TY - JOUR
T1 - Survival and associated comorbidities in inclusion body myositis
AU - Naddaf, Elie
AU - Shelly, Shahar
AU - Mandrekar, Jay
AU - Chamberlain, Alanna M.
AU - Hoffman, E. Matthew
AU - Ernste, Floranne C.
AU - Liewluck, Teerin
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Objective: To evaluate survival and associated comorbidities in inclusion body myositis (IBM) in a population-based, case-control study. Methods: We utilized the expanded Rochester Epidemiology Project medical records-linkage system, including 27 counties in Minnesota and Wisconsin, to identify patients with IBM, other inflammatory myopathies (IIM), and age/sex-matched population-controls. We compared the frequency of various comorbidities and survival among groups. Results: We identified 50 IBM patients, 65 IIM controls and 294 population controls. Dysphagia was most common in IBM (64%) patients. The frequency of neurodegenerative disorders (dementia/parkinsonism) and solid cancers was not different between groups. Rheumatoid arthritis was the most common rheumatic disease in all groups. A total of 36% of IBM patients had a peripheral neuropathy, 6% had Sjögren's syndrome and 10% had a haematologic malignancy. T-cell large granular lymphocytic leukaemia was only observed in the IBM group. None of the IBM patients had hepatitis B or C, or HIV. IBM patients were 2.7 times more likely to have peripheral neuropathy, 6.2 times more likely to have Sjögren's syndrome and 3.9 times more likely to have a haematologic malignancy than population controls. IBM was associated with increased mortality, with a 10-year survival of 36% from index, compared with 67% in IIM and 59% in population controls. Respiratory failure or pneumonia (44%) was the most common cause of death. Conclusions: IBM is associated with lower survival, and higher frequency of peripheral neuropathy, Sjögren's syndrome and haematologic malignancies than the general population. Close monitoring of IBM-related complications is warranted.
AB - Objective: To evaluate survival and associated comorbidities in inclusion body myositis (IBM) in a population-based, case-control study. Methods: We utilized the expanded Rochester Epidemiology Project medical records-linkage system, including 27 counties in Minnesota and Wisconsin, to identify patients with IBM, other inflammatory myopathies (IIM), and age/sex-matched population-controls. We compared the frequency of various comorbidities and survival among groups. Results: We identified 50 IBM patients, 65 IIM controls and 294 population controls. Dysphagia was most common in IBM (64%) patients. The frequency of neurodegenerative disorders (dementia/parkinsonism) and solid cancers was not different between groups. Rheumatoid arthritis was the most common rheumatic disease in all groups. A total of 36% of IBM patients had a peripheral neuropathy, 6% had Sjögren's syndrome and 10% had a haematologic malignancy. T-cell large granular lymphocytic leukaemia was only observed in the IBM group. None of the IBM patients had hepatitis B or C, or HIV. IBM patients were 2.7 times more likely to have peripheral neuropathy, 6.2 times more likely to have Sjögren's syndrome and 3.9 times more likely to have a haematologic malignancy than population controls. IBM was associated with increased mortality, with a 10-year survival of 36% from index, compared with 67% in IIM and 59% in population controls. Respiratory failure or pneumonia (44%) was the most common cause of death. Conclusions: IBM is associated with lower survival, and higher frequency of peripheral neuropathy, Sjögren's syndrome and haematologic malignancies than the general population. Close monitoring of IBM-related complications is warranted.
KW - Sjögren's syndrome
KW - case-control study
KW - inclusion body myositis
KW - large granular lymphocytic leukemia
KW - peripheral neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85115849797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115849797&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keab716
DO - 10.1093/rheumatology/keab716
M3 - Article
C2 - 34534271
AN - SCOPUS:85115849797
SN - 1462-0324
VL - 61
SP - 2016
EP - 2024
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 5
ER -